The PI3K/AKT pathway is frequently overactive in many types of cancer due to mutations, amplifications, or other alterations. This pathway's dysregulation contributes to tumor growth, survival, and resistance to conventional therapies. By inhibiting PDK1, we can potentially disrupt this pathway, thereby hindering cancer cell proliferation and inducing apoptosis. Thus, PDK1 inhibitors represent a promising strategy in the development of cancer therapeutics.
